
J&J opens office at Stevenage Bioscience Catalyst
pharmafile | June 21, 2013 | News story | Manufacturing and Production, Research and Development | J&J, JJ, bioscience, catalyst
Johnson & Johnson Innovation has establishment a partnering office at Stevenage Bioscience Catalyst to support emerging entrepreneurs and biotech firms in the region.
Science and business experts from the London Innovation Centre of J&J Innovation will have a regular presence at the Bioscience Catalyst to interact with companies in residence who are advancing concepts and technologies, with the potential to transform patient healthcare it says.
J&J adds that the collaboration with Stevenage Bioscience Catalyst reflects its commitment to the open innovation and collaboration that is necessary to tackle urgent unmet medical needs.
“Our goal in placing four regional innovation centers in life science hotspots such as London, is to integrate our science and business experts with innovators and entrepreneurs in these communities so that together we can support a strong biotech industry and advance promising healthcare solutions,” said Dr Kurt Hertogs, Incubator Strategy leader for J&J Innovation in the London Innovation Centre.
“Collaboration within the unique incubator environment of Stevenage Bioscience Catalyst, which was created to provide small organizations access to the resources of larger pharmaceutical companies, is one of the steps we can take to help advance these goals.”
Brett Wells
Related Content

J&J seek approval for first drug to treat high-risk smoldering myeloma
Earlier in November, Johnson & Johnson innovative medicine have applied to the US Food and …

European Commission approves combination chemotherapy for treatment of advanced EGFR-mutated non-small cell lung cancer in adult patients
Today, Janssen-Cilag International, part of Johnson & Johnson (J&J) has announced that the European Comission …

J&J seeks FDA approval of Spravato as monotherapy for treatment-resistant depression
Johnson & Johnson (J&J) has announced that it has submitted a supplemental New Drug Application …






